RTI-177

RTI-177 is a psychoactive drug and research chemical that belongs to the phenyltropane group of substances. It is primarily used in scientific research and has not been approved for medical use. RTI-177 is known for its high affinity for the dopamine transporter (DAT), which it binds to more selectively than other similar compounds.

Etymology

The name "RTI-177" is an abbreviation of "Research Triangle Institute-177", with the number 177 being a sequential identifier in the series of compounds developed by the institute. The Research Triangle Institute (RTI) is a nonprofit organization based in the Research Triangle Park in North Carolina, USA, which conducts research in various fields including drug development.

Pharmacology

RTI-177 acts as a potent dopamine reuptake inhibitor, meaning it blocks the reabsorption of dopamine into the pre-synaptic neuron, leading to an increase in the extracellular concentration of dopamine. This results in increased neurotransmission and allows for prolonged effects of dopamine in the synaptic cleft, which can lead to various psychoactive effects.

Related Compounds

RTI-177 is part of a larger family of phenyltropane-based compounds developed by RTI. Other notable compounds in this family include RTI-31, RTI-32, RTI-51, RTI-55, RTI-112, RTI-113, RTI-121, RTI-126, RTI-150, RTI-171, RTI-229, RTI-336, and RTI-371.

See Also

• Phenyltropane
• Dopamine reuptake inhibitor
• Research Triangle Institute

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia